Krsnaa Diagnostics Ltd (KRSNAA) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Krsnaa Diagnostics achieved 17% year-on-year revenue growth in the first nine months of FY25, reaching INR 5,311 million. This growth is attributed to increased awareness of service offerings and competitive pricing.
- EBITDA surged 39% year-on-year to INR 1,416 million, with margins improving to 27%.
- Net profit for nine months reached INR 569 million, matching the full-year profit of the previous year and demonstrating a focus on operational efficiency.
- Q3 FY25 revenue was impacted by seasonal variations, the conclusion of the Mumbai BMC project, and delayed ramp-up of installations in Maharashtra and Madhya Pradesh due to site handover delays.
- Operational challenges in Karnataka and Assam also contributed to short-term volume moderation.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.